Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-13.71 Insider Own0.20% Shs Outstand74.12M Perf Week-1.71%
Market Cap17.13B Forward P/E7.13 EPS next Y32.30 Insider Trans-56.72% Shs Float73.93M Perf Month-0.26%
Income-949.90M PEG- EPS next Q-3.91 Inst Own55.20% Short Float8.22% Perf Quarter18.48%
Sales1.18B P/S14.50 EPS this Y-32.00% Inst Trans-4.67% Short Ratio1.24 Perf Half Y4.75%
Book/sh10.06 P/B22.89 EPS next Y416.40% ROA-48.20% Target Price264.20 Perf Year109.07%
Cash/sh27.89 P/C8.26 EPS next 5Y0.00% ROE-150.90% 52W Range76.59 - 331.68 Perf YTD106.52%
Dividend- P/FCF28.91 EPS past 5Y9.50% ROI-38.00% 52W High-30.57% Beta1.53
Dividend %- Quick Ratio1.40 Sales past 5Y67.30% Gross Margin- 52W Low200.67% ATR15.85
Employees791 Current Ratio1.40 Sales Q/Q739.40% Oper. Margin-78.80% RSI (14)47.67 Volatility4.85% 6.18%
OptionableYes Debt/Eq0.58 EPS Q/Q- Profit Margin-80.40% Rel Volume0.58 Prev Close226.92
ShortableYes LT Debt/Eq0.45 EarningsAug 05 AMC Payout- Avg Volume4.90M Price230.29
Recom2.20 SMA20-5.11% SMA503.94% SMA20019.82% Volume2,841,163 Change1.49%
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Sep-21-21 05:50PM  
05:31PM  
03:25PM  
11:21AM  
05:51AM  
Sep-20-21 04:50PM  
04:46PM  
04:05PM  
02:23PM  
01:42PM  
Sep-17-21 04:41PM  
03:59PM  
03:56PM  
02:56PM  
02:29PM  
02:09PM  
01:42PM  
11:17AM  
05:51AM  
Sep-16-21 07:02PM  
10:40AM  
Sep-15-21 05:00PM  
02:40PM  
01:51PM  
01:00PM  
10:25AM  
06:00AM  
Sep-14-21 05:45PM  
06:20AM  
Sep-13-21 03:33PM  
02:14PM  
01:40PM  
01:16PM  
Sep-11-21 06:00AM  
05:55AM  
Sep-10-21 04:42PM  
04:31PM  
01:46PM  
12:26PM  
11:21AM  
06:52AM  
Sep-09-21 03:52PM  
03:28PM  
02:24PM  
10:33AM  
10:32AM  
09:25AM  
07:38AM  
Sep-08-21 01:37PM  
11:47AM  
08:48AM  
08:30AM  
08:16AM  
Sep-07-21 05:39PM  
02:12PM  
11:32AM  
09:05AM  
07:51AM  
Sep-06-21 10:53PM  
05:52AM  
Sep-05-21 05:51AM  
Sep-03-21 01:58PM  
06:00AM  
Sep-02-21 04:48PM  
03:23PM  
02:18PM  
Sep-01-21 06:01PM  
02:14PM  
12:10PM  
05:51AM  
Aug-31-21 04:37PM  
04:04PM  
03:36PM  
11:46AM  
08:18AM  
Aug-30-21 05:18PM  
04:37PM  
04:07PM  
02:06PM  
05:51AM  
Aug-29-21 11:45PM  
05:52AM  
Aug-27-21 02:07PM  
10:40AM  
06:06AM  
Aug-26-21 05:22PM  
03:02PM  
02:37PM  
Aug-25-21 06:06PM  
01:38PM  
12:03PM  
09:27AM  
Aug-24-21 05:29PM  
02:16PM  
11:45AM  
09:57AM  
09:40AM  
Aug-23-21 01:57PM  
05:50AM  
Aug-22-21 09:01AM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Gregory MPresident, R&DSep 15Option Exercise37.901,18344,8325,244Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Option Exercise19.085,00095,4005,706Sep 17 05:11 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Sale229.445,0001,147,193706Sep 17 05:11 PM
Glenn Gregory MPresident, R&DSep 15Sale229.341,183271,3044,061Sep 17 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 14Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 14Sale236.617,4991,774,360718Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Sale235.297,4991,764,433718Sep 15 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Option Exercise19.085,00095,4005,706Sep 03 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Sale247.975,0001,239,867706Sep 03 05:10 PM
Glenn Gregory MPresident, R&DAug 31Sale239.871,386332,4634,061Sep 01 05:23 PM
Glenn Gregory MPresident, R&DAug 26Option Exercise5.956,92141,1808,228Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 26Sale233.924,167974,7404,061Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 16Option Exercise40.641,86675,8265,927Aug 18 05:26 PM
Glenn Gregory MPresident, R&DAug 16Sale233.521,866435,7504,061Aug 18 05:26 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Option Exercise14.832,89642,9603,602Jul 28 05:00 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Sale197.742,896572,648706Jul 28 05:00 PM
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Sale239.832,895694,317275May 04 06:03 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.56221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26243,054Sep 30 09:30 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM